Loss of the Pioneer Factor FOXA1 Results in Genome-wide Epigenetic Reprogramming and activation of Interferon-Response Genes including CD274/PD-L1

Forkhead Box A1 (FOXA1) is a pioneer transcription factor critical in epigenetic regulation of chromatin and cell fate determination. Reduced FOXA1 expression is an independent predictor of poor overall survival in bladder cancer patients. However, the impact of FOXA1 loss on chromatin epigenetics in bladder cancer is unknown. Therefore, we determined the impact of FOXA1 knock out (KO) on epigenetic modification of chromatin and associated gene expression. We identified 8,230 differentially expressed genes following FOXA1 KO. Surprisingly, Gene Set Enrichment Analysis (GSEA) identified IFNɑ/ɣ gene expression signatures as enriched following FOXA1 KO. FOXA1 KO induced both increased and decreased numbers of histone 3 lysine 27 acetylation (H3K27ac) sites throughout the genome. As expected, the majority of differences in H3K27ac across genomic areas in FOXA1 KO cells is mapped to intergenic and intronic regions where enhancers reside. In addition, a subset of differential H3K27ac levels were also mapped to proximal promoters and within gene bodies. Integrated analysis of RNA/ChIP-seq data shows changes in gene expression that are mirrored by differences in H3K27ac. Motif analysis of DNA sequence enriched for H3K27ac identified significant increases in transcription factor binding motifs including the interferon sensitive response element (ISRE) and interferon response factors such as IRF1. Moreover, we identified increased H3K27ac of regulatory elements as being associated with several upregulated interferon sensitive genes (ISGs) in FOXA1 KO cells, including CD274/PD-L1. Western blotting and Q-RT-PCR confirmed upregulation of CD274/PD-L1 following FOXA1 KO. Analysis of TCGA data confirmed an inverse relationship between FOXA1 and CD274 in bladder cancer, as well as in other cancers. In summary, we provide evidence of widespread epigenetic reprogramming after FOXA1 KO in bladder cancer cells. Additionally, we provide evidence that FOXA1 KO-induced epigenetic changes contribute to activation of a global interferon-dominant expression signature, including the immune checkpoint target CD274/PD-L1 in a cancer cell-intrinsic manner.

[1]  R. Schiff,et al.  FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer , 2019, Proceedings of the National Academy of Sciences.

[2]  K. Kaestner,et al.  Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer , 2019, Oncogene.

[3]  Jindan Yu,et al.  Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression , 2019, Cell Research.

[4]  A. Chinnaiyan,et al.  Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer , 2019, Nature.

[5]  Christina S. Leslie,et al.  FOXA1 mutations alter pioneering activity, differentiation, and prostate cancer phenotypes , 2019, Nature.

[6]  J. Lerner,et al.  A changing paradigm of transcriptional memory propagation through mitosis , 2018, Nature Reviews Molecular Cell Biology.

[7]  Brandon Da Silva,et al.  Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis , 2017, Cell.

[8]  Feng Yue,et al.  FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines , 2016, Scientific Reports.

[9]  K. Kaestner,et al.  The Pioneer Transcription Factor FoxA Maintains an Accessible Nucleosome Configuration at Enhancers for Tissue-Specific Gene Activation. , 2016, Molecular cell.

[10]  Opal L. Reddy,et al.  METABOLIC , ENDOCRINE , AND GENITOURINARY PATHOBIOLOGY Loss of FOXA 1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer , 2015 .

[11]  X. Montalban,et al.  FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS , 2014, Nature Medicine.

[12]  Shahrokh F. Shariat,et al.  Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation , 2012, PloS one.

[13]  Zhaoyu Li,et al.  Foxa1 and Foxa2 Are Essential for Sexual Dimorphism in Liver Cancer , 2012, Cell.

[14]  J. Carroll,et al.  Pioneer transcription factors: establishing competence for gene expression. , 2011, Genes & development.

[15]  R. Young,et al.  Histone H3K27ac separates active from poised enhancers and predicts developmental state , 2010, Proceedings of the National Academy of Sciences.

[16]  K. Kaestner,et al.  The FoxA factors in organogenesis and differentiation. , 2010, Current opinion in genetics & development.

[17]  T. Sekiya,et al.  Nuclear mobility and mitotic chromosome binding: similarities between pioneer transcription factor FoxA and linker histone H1. , 2010, Cold Spring Harbor symposia on quantitative biology.

[18]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[19]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[20]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[21]  R. Caprioli,et al.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.

[22]  Renjie Jin,et al.  The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. , 2003, Molecular endocrinology.

[23]  Frank R. Lin,et al.  Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. , 2002, Molecular cell.